Cardiovascular Risk of Proton Pump Inhibitors

Hannah Ariel; John P. Cooke

doi:10.14797/mdcj-15-3-214

Cardiovascular Risk of Proton Pump Inhibitors

Methodist DeBakey Cardiovascular Journal

Volume 15 (2019): Issue 3

By: Hannah Ariel and John P. Cooke

Open Access

|Jul 2019

Abstract

Proton pump inhibitors (PPIs) are effective agents for the treatment of gastroesophageal reflux (GERD). However, these drugs have not been approved for long-term use. Now sold over the counter, these agents are being used chronically for GERD without medical supervision. The long-term use of PPIs may have significant adverse effects, in part mediated by their effect of accelerating vascular aging. Physicians should assist patients in tapering off their use of PPIs and replacing them with lifestyle modifications and/or other agents that have better long-term safety profiles.

References

Pharmacist's Letter [Internet] Stockton, CA Therapeutic Research Center 2019 Proton pump inhibitors: appropriate use and safety concerns; 2019 Feb [cited 2019 Mar 27]. Available from: https://pharmacist.therapeuticre-search.com/Home/PL (#350214)
Search in Google Scholar Back to article
Heidelbaugh JJ Kim AH Chang R Walker PC Overutilization of proton-pump inhibitors: what the clinician needs to know Therap Adv Gastroenterol 2012 Jul 5 4 219 32
Search in Google Scholar Back to article
Katz MH Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users Arch Intern Med 2010 170 9 747 8
Search in Google Scholar Back to article
Eid SM Boueiz A Paranji S Mativo C Landis R Abougergi MS Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists Intern Med 2010 49 23 2561 8
Search in Google Scholar Back to article
Lamberts R Brunner G Solcia E Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa Digestion 2001 64 4 205 13
Search in Google Scholar Back to article
Waldum HL Qvigstad G Fossmark R Kleveland PM Sandvik AK Rebound acid hyper-secretion from a physiological, pathophysiological and clinical viewpoint Scand J Gastroenterol. 2010 Apr 45 4 389 94
Search in Google Scholar Back to article
Wedemeyer RS Blume H Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update Drug Saf 2014 Apr 37 4 201 11
Search in Google Scholar Back to article
Ho PM Maddox TM Wang L Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 2009 Mar 4 301 9 937 44
Search in Google Scholar Back to article
Bhatt DL Cryer BL Contant CF Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 2010 Nov 11 363 20 1909 17
Search in Google Scholar Back to article
Cardoso RN Benjo AM DiNicolantonio JJ Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis Open Heart 2015 June 30 2 1 e00248
Search in Google Scholar Back to article
Kwok CS Jeevantham V Dawn B Loke YK No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis Int J Cardiol 2013 Aug 10 167 3 965 74
Search in Google Scholar Back to article
Melloni C Washam JB Jones WS Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when co-administered with dual antiplatelet therapy: systematic review Circ Cardiovasc Qual Outcomes 2015 Jan 8 1 47 55
Search in Google Scholar Back to article
Yoshihisa A Takiguchi M Kanno Y Associations of Acid Suppressive Therapy With Cardiac Mortality in Heart Failure Patients J Am Heart Assoc 2017 May 16 6 5
Search in Google Scholar Back to article
Shah NH LePendu P Bauer-Mehren A Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population PLoS One 2015 Jun 10 10 6 e0124653
Search in Google Scholar Back to article
Shih CJ Chen YT Ou SM Li SY Chen TJ Wang SJ Proton pump inhibitor use represents an independent risk factor for myocardial infarction Int J Cardiol 2014 Nov 15 177 1 292 7
Search in Google Scholar Back to article
Xie Y Bowe B Li T Xian H Yan Y Al-Aly Z Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans BMJ Open 2017 Jul 4 7 6 e015735
Search in Google Scholar Back to article
Perazella MA Proton pump inhibitors and hypomagnesemia: a rare but serious complication Kidney International 2013 Apr 83 4 553 6
Search in Google Scholar Back to article
Toh JW Ong E Wilson R Hypomagnesaemia associated with long-term use of proton pump inhibitors Gastroenterol Rep (Oxf) 2015 Aug 3 3 243 53
Search in Google Scholar Back to article
Leto L Aspromonte N Feola M Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review Heart Fail Rev 2014 Mar 19 2 237 46
Search in Google Scholar Back to article
Wargo KA Banta WM A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother 2009 Nov 43 11 1836 47
Search in Google Scholar Back to article
Prescribers Digital Reference [Internet] Whippany, NJ PDR, LLC 2019 Plavix (clopidogrel bisulfate) FDA Drug Safety Communication; 2009 Nov 17 [cited 2019 Mar 28]. Available from: https://www.pdr.net/fda-drug-safety-communication/plavix?druglabelid=525&id=5033
Search in Google Scholar Back to article
Ghebremariam YT LePendu P Lee JC Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine Circulation 2013 Aug 20 128 8 845 53
Search in Google Scholar Back to article
Wilson AM Shin DS Weatherby C Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease Vasc Med 2010 Aug 15 4 267 74
Search in Google Scholar Back to article
Cooke JP Flow, NO, and atherogenesis Proc Natl Acad Sci U S A 2003 Feb 4 100 3 768 70
Search in Google Scholar Back to article
Yepuri G Sukhovershin R Nazari-Shafti TZ Petrascheck M Ghebre YT Cooke JP Proton Pump Inhibitors Accelerate Endothelial Senescence Circ Res 2016 Jun 10 118 12 e36 42
Search in Google Scholar Back to article
Mindell JA Lysosomal acidification mechanisms Annu Rev Physiol 2012 74 69 86
Search in Google Scholar Back to article
Gomm W von Holt K Thome F Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis JAMA Neurol 2016 Apr 73 4 410 6
Search in Google Scholar Back to article
Lazarus B Chen Y Wilson FP Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease JAMA Intern Med 2016 Feb 176 2 238 46
Search in Google Scholar Back to article
Charlot M Ahlehoff O Norgaard ML Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study Ann Intern Med 2010 Sep 21 153 6 378 86
Search in Google Scholar Back to article
Charlot M Grove EL Hansen PR Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study BMJ 2011 May 342 d2690
Search in Google Scholar Back to article
Xu J Murphy SL Kochanek KD Arias E Mortality in the United States, 2015 NCHS Data Brief 2016 Dec 267 1 8
Search in Google Scholar Back to article
Kim J Blackett JW Jordokovsky D Strategies for effective discontinuation of proton pump inhibitors Curr Gastroenterol Rep 2018 May 16 20 6 27
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.14797/mdcj-15-3-214 | Journal eISSN: 1947-6108

Journal RSS Feed

Language: English

Page range: 214 - 219

Published on: Jul 1, 2019

Published by: Houston Methodist DeBakey Heart & Vascular Center

In partnership with: Paradigm Publishing Services

Keywords:

proton pump inhibitor,

H2 antagonists,

gastroesophageal reflux disease,

GERD

© 2019 Hannah Ariel, John P. Cooke, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.

Volume 15 (2019): Issue 3